Table 2

Variables associated with the evolution of the disease activity score from 28-joint count with three parameters (DAS28-3), the Health Assessment Questionnaire (HAQ) score, and the Larsen score in the EMECAR cohort

DAS28-3
 HAQ score
 Larsen score


Bivariate
 Multivariate
 Bivariate
 Multivariate
 Bivariate
 Multivariate
Female gender
 0.57 (0.36 to 0.78)***
 -
 0.42 (0.29 to 0.55)***
 -
 6.49 (1.53 to 11.45)*
 -
Age at baseline
 0.001 (-0.006 to 0.007)
 -
 0.004 (0 to 0.008)*
 0.002 (0 to 0.004)*
 -0.19 (-0.34 to -0.03)*
 0.009 (-0.025 to 0.043)
Age at disease onset
 0.006 (-0.002 to 0.007)
 0.002 (-0.002 to 0.007)
 0.20 (0.016 to 0.024)***
 -
 0.57(0.42 to 0.73)
 -
Disease duration
 0.004 (-0.007 to 0.015)
 -
 0.017 (0.009 to 0.024)***
 -
 0.94 (0.55 to 1.34)***
 -
Extra-articular rheumatoid arthritis
 0.32 (0.15 to 0.4)***
 0.16 (0.04 to 0.28)*
 0.22 (0.13 to 0.31)***
 0.03 (-0.02 to 0.09)
 0.06 (6.35 to 11.76)***
 -
Rheumatoid factor
 0.19 (-0.03 to 0.41)
 0.02 (-0.12 to 0.16)
 0.14 (0.01 to 0.28)*
 0.03 (-0.04 to 0.1)
 7.96 (3.19 to 12.72)**
 0.71 (-0.37 to 1.80)
Hemoglobin (g/dl)
 -0.29 (-0.34 to -0.25)***
 -0.19(-0.23 to -0.15)***
 -0.1 (-0.12 to -0.07)***
 -0.03 (-0.05 to -0.01)**
 -0.95 (-1.61 to -0.28)**
 -0.04 (-0.32 to 0.25)
Hypertension
 0.05 (-0.11 to 0.21)
 -
 0.19 (0.11 to 0.27)***
 0.05 (-0.01 to 0.11)
 2.74 (0.4 to 5.08)*
 -0.34 (-1.3 to 0.61)
Diabetes mellitus
 -0.01 (-0.27 to 0.24)
 -
 0.07 (-0.08 to 0.22)
 -
 -1.87 (-6.54 to 2.8)
 -
Hyperlipidemia
 -0.14 (-0.31 to 0.03)
 0.08 (-0.05 to 0.21)
 -0.5 (-0.14 to 0.04)
 -
 -1.44 (-4.71 to 1.84)
 -
Peptic ulcer
 0.17 (-0.13 to 0.47)
 -
 0.15 (0.02 to 0.28)*
 0.05 (-0.03 to 0.13)
 1.30 (-3.06 to 5.66)
 -
Myocardial ischemia
 -0.05 (-0.33 to 0.23)
 -
 0.17 (-0.08 to to0.42)
 0.06 (-0.09 to 0.21)
 -0.49 (-6.56 to 5.58)
 -
Heart failure
 0.31 (0.04 to 0.59)*
 0.06 (-0.21 to 0.33)
 0.36 (0.21 to 0.50)***
 -
 -0.74 (-7.21 to 5.72)
 -
Stroke
 0.15 (-0.2 to 0.49)
 -
 0.02 (-0.27 to 0.3)
 -
 -8.94 (-13.79 to -4.09)***
 -
Chronic obstructive pulmonary disease
 -0.1 (-0.38 to 0.17)
 -
 0.01 (-0.13 to 0.14)
 -
 2.2 (-3.23 to 7.64)
 -
Neoplasm
 -0.29 (-0.61 to 0.03)
 -
 0.01 (-0.12 to 0.14)
 -
 -1.96 (-9.92 to 6.01)
 -
Liver disease
 0.11 (-0.1 to 0.33)
 -
 -0.2 (-0.11 to 0.08)
 -
 -3.63 (-9.01 to 1.76)
 -2.57 (-5.07 to -0.07)*
Depression
 0.27 (0.09 to 0.46)**
 0.12 (-0.03 to 0.26)
 0.15 (0.05 to 0.25)**
 0.02 (-0.05 to 0.09)
 -0.79 (-3.61 to 2.03)
 -
Body mass index
 0 (-0.02 to 0.02)
 -
 0.01 (0 to 0.02)
 0 (-0.01 to 0)
 -0.78 (-1.16 to -0.4)***
 -0.16 (-0.65 to 0.33)
DAS28-3 (each visit)
 -
 -
 0.17 (0.15 to 0.19)***
 0.15 (0.13 to 0.17)***
 0.37 (-0.23 to 0.98)
 -
DAS28-3 (baseline)
 0.62 (0.57 to 0.67)***
 0.53 (0.48 to 0.59)***
 0.24 (0.2 to 0.28)***
 -0.1 (-0.13 to -0.07)***
 6.79 (5.42 to 8.15)***
 0.68 (0.26 to 1.11)**
HAQ score (each visit)
 -
 -
 -
 -
 4.92 (3.61 to 6.24)***
 -
HAQ score (baseline)
 -
 -
 0.85 (0.82 to 0.88)***
 0.82 (0.78 to 0.86)***
 -
 -
Larsen score (baseline)
 -
 -
 -
 -
 0.97 (0.95 to 0.99)***
 0.96 (0.94 to 0.98)***
Year





∘ 2000
 Reference
 Reference
 Reference
 Reference
 Reference
 Reference
∘ 2001
 -0.3 (-0.4 to -0.2)***
 -0.23 (-0.33 to -0.13)***
 0.01 (-0.03 to 0.05)
 0.04 (-0.02 to 0.09)
 NA
 NA
∘ 2002
 -0.32 (-0.43 to -0.21)***
 -0.27 (-0.38 to -0.15)***
 0.06 (0.01 to 0.11)*
 0.07 (0.01 to 0.13)*
 2.09 (1.32 to 2.86)***°
 2.07 (1.1 to 3.04)***
∘ 2003
 -0.47 (-0.58 to -0.36)***
 -0.4 (-0.53 to -0.27)***
 0.05 (0 to 0.11)
 0.11 (0.04 to 0.18)**
 NA
 NA
∘ 2004
 -0.5 (-0.63 to -0.37)***
 -0.43 (-0.58 to -0.28)***
 0.09 (0.03 to 0.15)**
 0.15 (0.07 to 0.22)
 4.18 (2.68 to 5.68)***
 4.4 (2.68 to 6.12)***

Data presented as β coefficient (95% confidence interval). NA, not available. ***P < 0.001, **P < 0.01, *P < 0.05.

González-Alvaro et al. Arthritis Research & Therapy 2008 10:R138   doi:10.1186/ar2561